.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Refining Therapeutic Strategies for Follicular Lymphoma

EP. 1: Follicular Lymphoma: Outcomes After Immunochemotherapy

January 5th 2018

EP. 2: Upfront Therapy Strategies in Follicular Lymphoma

January 5th 2018

EP. 3: Challenging the Role of Maintenance Therapy in FL

January 5th 2018

EP. 4: Predicting and Analyzing Response in Follicular Lymphoma

January 5th 2018

EP. 5: Choosing Second-Line Therapy for Relapsed/Refractory FL

January 5th 2018

EP. 6: Third-Line Treatment for FL: PI3 Kinase Inhibitors

January 5th 2018

EP. 7: Follicular Lymphoma: Optimizing Novel Agent Therapy

January 5th 2018

EP. 8: Follicular Lymphoma: Novel Approaches With Rituximab

January 5th 2018

EP. 9: Novel Agents in FL: Unmet Needs and Potential Uses

January 5th 2018

EP. 10: FL: Potential for SYK/JAK Inhibitors or Azacitidine

January 5th 2018

EP. 11: Immunotherapy in the Treatment of Follicular Lymphoma

January 5th 2018

EP. 12: The Future Treatment of Follicular Lymphoma

January 5th 2018